FcRH5/CD3 Bispecific Antibody Dosing Guided by Ki-67 T-Cell Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple myeloma, particularly relapsed or refractory cases, are inadequate, with limited survival benefits and a high relapse rate, necessitating the development of novel therapeutic agents like bispecific antibodies that offer a favorable benefit-risk profile.
Innovation Solution
The use of bispecific antibodies targeting FcRH5 and CD3, with monitoring and dosing strategies based on T cell proliferation markers (Ki-67) and MKI67+ T cells to assess and adjust treatment, ensuring continued administration in response and cessation in non-response scenarios.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for relapsed or refractory multiple myeloma are used, then treatment options are limited, but survival benefit is insufficient and relapse rate remains high
Solution Approach 1:
The patent introduces a novel therapeutic approach by changing the fundamental parameter of treatment mechanism - using bispecific antibodies that simultaneously bind to FcRH5 on myeloma cells and CD3 on T cells, thereby transforming the treatment paradigm from conventional cytotoxic or immunomodulatory approaches to T cell-mediated immunotherapy, which improves survival benefit while providing a new treatment option for R/R MM
Solution Approach 2:
The bispecific antibody functions as a composite therapeutic agent that combines two specific binding functions into a single molecule - one arm targets FcRH5 on myeloma cells while the other arm targets CD3 on T cells, creating a bifunctional therapeutic that bridges tumor cells and immune cells to elicit targeted anti-tumor immunity
2Reliability
If bisspecific antibody treatment is administered, then treatment efficacy is improved, but dosing optimization is needed to maximize benefit-risk profile
Solution Approach 1:
The patent implements a feedback-based dosing strategy by monitoring T cell proliferation markers (Ki-67 expression) in patient samples to assess treatment response. This feedback mechanism allows dynamic adjustment of dosing - continuing treatment when proliferation markers indicate response, and modifying or discontinuing treatment when markers indicate lack of response or excessive toxicity, thereby optimizing the benefit-risk profile
Solution Approach 2:
The dosing strategy transitions from static fixed-dose regimens to dynamic adaptive dosing based on real-time biomarker assessment. Treatment duration and dosage are adjusted according to the dynamic state of T cell proliferation markers, allowing the therapy to adapt to individual patient responses and maximize efficacy while minimizing toxicity
3Adaptability or versatility
If T cell proliferation markers are monitored to guide dosing, then treatment personalization is improved, but measurement and monitoring complexity increases
Solution Approach 1:
The patent employs flow cytometry-based detection methods that utilize fluorescent markers to visualize and quantify Ki-67 expression on T cells. The fluorescent signals act as optical indicators that allow automated or semi-automated measurement of proliferation markers, transforming a complex cellular assessment into a measurable signal that can be quantified and used for treatment decision-making
Data Source
AI summary
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.